International Phase I Trial of Dinutuximab Beta With VDC/IE in GD2-Positive Ewing Sarkoma

The goal of the study is to investigate the feasibility, toxicity, and biological activity of the treatment with dinutuximab beta in combination with standard chemotherapy in EWS to give high-risk patients with a GD2 positiv pumor a benefit in treatment. Within the study is tested with three different dosages in a 3+3 design with three pre-defined dose levels.

Trial Details

NCT ID
NCT06839703
Phase
PHASE1
Sponsor
Prof. Dr. Dr. Birgit Burkhardt
Status
RECRUITING
Cancer Type
Sarcoma
Interventions
  • Dinutuximab beta
Locations (sample)
  • Göttingen, Lower Saxony, Germany|51.53443,9.93228
  • Greifswald, Mecklenburg-Vorpommern, Germany|54.08905,13.40244
  • Essen, North Rhine-Westfalia, Germany|51.45657,7.01228
  • Mainz, Rhineland-Palatinate, Germany|49.98185,8.28008
  • Berlin, State of Berlin, Germany|52.52437,13.41053

Key Eligibility Criteria

  • Histologically confirmed, newly diagnosed Ewing Sarcoma (m/f/d) or so-called Ewing-like sarcoma (i.e. translocation-positive small blue round cell …
  • High risk stratification (metastatic disease)
  • Centrally confirmed GD2-positive tumor (biopsy of original and/or residual tumor or liquid biopsy in peripheral blood)
  • Availability of fresh frozen tumor tissue for central GD2-detection

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Sarcoma Trials on Trialify →